Viewing Study NCT06637007



Ignite Creation Date: 2024-10-26 @ 3:42 PM
Last Modification Date: 2024-10-26 @ 3:42 PM
Study NCT ID: NCT06637007
Status: RECRUITING
Last Update Posted: None
First Post: 2024-10-08

Brief Title: Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma
Sponsor: None
Organization: None

Study Overview

Official Title: Single Arm Open Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma
Status: RECRUITING
Status Verified Date: 2024-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Evaluation of the efficacy and safety of Xidabenzamide combined with AK112 for advanced bone and soft tissue sarcoma of second-line and above
Detailed Description: Evaluation of the efficacy and safety of Xidabenzamide combined with AK112 for advanced bone and soft tissue sarcoma of second-line and above

Main objective To explore the objective response rate ORR and progression free survival PFS of Xidabenzamide combined with AK112 for disease stability in advanced bone and soft tissue sarcoma of second-line and above Secondary objective To explore the overall survival OS quality of life QOL safety and tolerability indicators of Xidabenzamide combined with AK112 for advanced bone and soft tissue sarcoma of second-line and above

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None